Scientists develop personalized cancer vaccines

Moderna and Merck announced that their phase III trial results for a personalized treatment against melanoma skin cancer were positive. It was proven that the therapy relies on mRNA technology and is custom-made for each patient based on their genetic signature. The treatment is administered after surgery to help the immune system target remaining cancer cells and prevent recurrence or spread. The trial involved 1,137 patients whose tumors were surgically removed and was divided into two groups: one received the vaccine combined with the immunotherapy drug Keytruda, while the other received only the immunotherapy. The results showed that combining the two treatments enhanced immune response and reduced the risk of cancer recurrence and metastasis. The companies are now awaiting the release of detailed data and final analysis. This marks the first successful phase III outcome for a personalized cancer treatment based on mRNA technology. The vaccine is produced by taking a tumor sample, analyzing its genetic sequence, and then designing a vaccine that carries instructions targeting the tumor's unique mutations. This approach allows for potentially more precise targeting of cancer cells and paves the way for personalized therapies for patients.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل